58106-26-6

Basic information

• Product Name: 2,5-DIMETHYL-4-METHOXYBENZOIC ACID
• Synonyms: RARECHEM AL BE 0535;2,5-DIMETHYL-4-METHOXYBENZOIC ACID;4-Methoxy-2,5-diMethylbenzoic acid
• CAS NO: 58106-26-6
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.2
• Mol File: 58106-26-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,5-DIMETHYL-4-METHOXYBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-DIMETHYL-4-METHOXYBENZOIC ACID(58106-26-6)
• EPA Substance Registry System: 2,5-DIMETHYL-4-METHOXYBENZOIC ACID(58106-26-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 58106-26-6(Hazardous Substances Data)

Usage

General Description

2,5-DIMETHYL-4-METHOXYBENZOIC ACID is a chemical compound with the molecular formula C11H14O3. It is a derivative of benzoic acid and is also known as p-Anisic acid. 2,5-DIMETHYL-4-METHOXYBENZOIC ACID is a white crystalline solid that is sparingly soluble in water but soluble in organic solvents such as ethanol and ether. It is commonly used in the production of fragrances and flavors, as well as in the synthesis of pharmaceuticals and cosmetics. 2,5-DIMETHYL-4-METHOXYBENZOIC ACID has antimicrobial properties and is often used as a preservative in various products. It also has potential applications in the field of polymer chemistry and can be used as an additive in polymer materials to improve their thermal and mechanical properties.

Upstream product

• 6880-04-2 4-methoxy-3-methylbenzoic acid 
• 95-78-3 2,5-Dimethylaniline 
• 85231-15-8 4-formyl-2,5-dimethylphenol 
• 95-87-4 2,5-Dimethylphenol 
• 67-66-3 chloroform 
• 10028-15-6 ozone 
• 6745-75-1 2,5-dimethyl-p-anisaldehyde 
• 67-64-1 acetone 

Downstream Products

• 27021-04-1 4-hydroxy-2,5-dimethyl-benzoic acid 
• 27023-05-8 methyl 4-hydroxy-2,5-dimethylbenzoate 

Relevant articles and documents

Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure-activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.